相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies
Antoinette R. Tan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)
Ruud van der Noll et al.
INVESTIGATIONAL NEW DRUGS (2020)
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Bhavana Pothuri et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).
Priyanka Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
Rachel M. Hurley et al.
GYNECOLOGIC ONCOLOGY (2019)
Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
Erika J. Lampert et al.
Oncotarget (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Leonard J. Appleman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors
Florence Atrafi et al.
CLINICAL CANCER RESEARCH (2019)
Exploring and comparing adverse events between PARP inhibitors
Christopher J. LaFargue et al.
LANCET ONCOLOGY (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Heidi J. Gray et al.
GYNECOLOGIC ONCOLOGY (2018)
The shieldin complex mediates 53BP1-dependent DNA repair
Sylvie M. Noordermeer et al.
NATURE (2018)
What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?
Katherine Ferry-Galow et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Ivana Gojo et al.
CLINICAL CANCER RESEARCH (2017)
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types
Jing Niu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Phase I study of veliparib in combination with gemcitabine
Ronald Stoller et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Jacob D. Soumerai et al.
CLINICAL CANCER RESEARCH (2017)
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo et al.
CLINICAL CANCER RESEARCH (2017)
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit et al.
CLINICAL CANCER RESEARCH (2017)
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Eve T. Rodler et al.
CLINICAL CANCER RESEARCH (2016)
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Miguel A. Villalona-Calero et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Miguel A. Villalona-Calero et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
J. Balmana et al.
ANNALS OF ONCOLOGY (2014)
Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies
Ahmed Hamed Salem et al.
CLINICAL PHARMACOKINETICS (2014)
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Jung-Min Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Final results of a phase 1 study of single-agent veliparib (V) in patients (pis) with either BRCA1/2-mutated cancer (BRCA plus ), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).
Shannon Puhalla et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Matteo Berti et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents
Wenrui Duan et al.
TRANSLATIONAL RESEARCH (2013)
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer
Rebecca A. Dent et al.
BREAST CANCER RESEARCH (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2012)
Role of PARP Inhibitors in Cancer Biology and Therapy
D. Davar et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
Anand G. Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Norman Chan et al.
CANCER RESEARCH (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion
Juergen Hummel et al.
PHARMACEUTICAL STATISTICS (2009)
Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase
Robert A. Parise et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
Cherrie K. Donawho et al.
CLINICAL CANCER RESEARCH (2007)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
V Schreiber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO
DM Euhus et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
M Esteller et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
